



Malmö 28 February 2024

PRESS RELEASE

Aptahem's scientific manuscript now published in the journal Cells

Aptahem announced on the 27 February 2024 that the company's scientific manuscript had been accepted for publication in the journal Cells. Today, the 28 February 2024, the paper has been published.

The title of the manuscript is "*Therapeutic effects of a novel aptamer on coronaviral infection induced lung injury and systemic inflammatory responses*" and can be [accessed via this link](#). The manuscript describes the results of the preclinical studies performed in SARS Corona virus models in collaboration with the research group in Toronto, which indicate that Apta-1 has therapeutic effects on coronaviral infection-induced acute lung injury and systemic inflammatory responses.

For further information:

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.